Loading organizations...
§ Private Profile · Waltham, MA, USA
Developing antibody therapy for severe asthma treatment.
Upstream Bio has raised $400.0M across 2 funding rounds.
Upstream Bio has raised $400.0M in total across 2 funding rounds.
Upstream Bio has raised $400.0M across 2 funding rounds. Most recently, it raised $200.0M Series B in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 8, 2023 | $200M Series B | EDD Fleming, Alex Rosen | Access Biotechnology, Altshuler Shaham, Bain Capital Life Sciences, Decheng Capital, HBM Healthcare Investments, Omega Funds, OrbiMed, Samsara BioCapital, TCGX, Wellington Management | Announced |
| Jun 2, 2022 | $200M Series A | Maruho, Erez Chimovits, OrbiMed | Access Biotechnology, Altshuler Shaham, Decheng Capital, HBM Healthcare Investments, Omega Funds, Samsara BioCapital, Bernard Davitian, TCGX | Announced |
Upstream Bio has raised $400.0M in total across 2 funding rounds.
Upstream Bio's investors include Edd Fleming, Alex Rosen, Access Biotechnology, Altshuler Shaham, Bain Capital Life Sciences, Decheng Capital, HBM Healthcare Investments, Omega Funds, OrbiMed, Samsara BioCapital, TCGX, Wellington Management.